Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| TEVA PHARMACEUTICAL INDUSTRIES LTDTEVA · Entity 3063 | EVP Global Brand&Communication | March 04, 2019 | March 06, 2019 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
TEVA PHARMACEUTICAL INDUSTRIES LTD
Report date March 04, 2019 · Filed March 06, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Restricted Share UnitsSEC Table II · derivative / convertible security | Direct | 26,865 |
Reported balance
After 2019-03-04 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2019-03-04 · Grant · Acquired 26,865 · Balance 26,865 F1: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F2: Restricted share units were granted on March 4, 2019, with 8,955 vesting on each of March 4, 2021, March 4, 2022 and March 4, 2023. F3: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. |
Filing footnotes · ownership attribution and instrument terms
F1: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.
F2: Restricted share units were granted on March 4, 2019, with 8,955 vesting on each of March 4, 2021, March 4, 2022 and March 4, 2023.
F3: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 04, 2019 Filed Mar 6, 2019 12:01 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | GrantRestricted Share Units · Derivative | 26,865 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-017225 · doc4.xml · derivative · entry 1 Codner Iris Beck · CIK 0001721514 · EVP Global Brand&Communication 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,865 Underlying: Ordinary Shares · 26,865 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F2 · derivative.exercise_date: Restricted share units were granted on March 4, 2019, with 8,955 vesting on each of March 4, 2021, March 4, 2022 and March 4, 2023. F2 · derivative.expiration_date: Restricted share units were granted on March 4, 2019, with 8,955 vesting on each of March 4, 2021, March 4, 2022 and March 4, 2023. F3 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| February 14, 2019 Filed Feb 19, 2019 11:58 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionRestricted Share Units · Derivative | 3,212 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-010833 · doc4.xml · derivative · entry 2 Codner Iris Beck · CIK 0001721514 · EVP Global Brand&Communication 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,425 Underlying: Ordinary Shares · 3,212 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F3 · derivative.exercise_date: Restricted share units were granted on February 14, 2017, with 3,212 vesting on each of February 14, 2019 and February 14, 2020 and 3,213 vesting on February 14, 2021. F3 · derivative.expiration_date: Restricted share units were granted on February 14, 2017, with 3,212 vesting on each of February 14, 2019 and February 14, 2020 and 3,213 vesting on February 14, 2021. F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| February 14, 2019 Filed Feb 19, 2019 11:58 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionOrdinary Shares | 3,212 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-19-010833 · doc4.xml · nonDerivative · entry 1 Codner Iris Beck · CIK 0001721514 · EVP Global Brand&Communication 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,996.0357 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2 · price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. Read SEC document |
| February 12, 2019 Filed Feb 14, 2019 12:40 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | GrantOrdinary Shares | 6,494 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-19-009988 · doc4.xml · nonDerivative · entry 1 Codner Iris Beck · CIK 0001721514 · EVP Global Brand&Communication 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,784.0357 F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2 · price: The Ordinary Shares were received for no consideration upon the satisfaction of performance criteria underlying an award of performance share units. Read SEC document |
| August 09, 2018 Filed Aug 13, 2018 12:34 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | SaleOrdinary Shares | 4,165 | $22.70 | $94,541.34 |
DisclosureSEC source: 0001209191-18-046335 · doc4.xml · nonDerivative · entry 1 Codner Iris Beck · CIK 0001721514 · EVP Global Brand&Communication 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,290.0357 F1 · price: The Ordinary Shares were sold in New Israeli Shekels. The price shown is calculated based on the exchange rate of NIS 3.683 per $1.00, as published by the Bank of Israel on August 9, 2018. Read SEC document |
| February 09, 2018 Filed Feb 12, 2018 21:29 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | GrantRestricted Share Units · Derivative | 34,031 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-009214 · doc4.xml · derivative · entry 2 Codner Iris Beck · CIK 0001721514 · EVP Global Brand&Communication 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,031 Underlying: Ordinary Shares · 34,031 shares Expires not disclosed F3 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F4 · derivative.exercise_date: Restricted share units were granted on February 9, 2018, with 11,343 vesting on each of February 9, 2020 and February 9, 2021 and 11,345 vesting on February 9, 2022. F4 · derivative.expiration_date: Restricted share units were granted on February 9, 2018, with 11,343 vesting on each of February 9, 2020 and February 9, 2021 and 11,345 vesting on February 9, 2022. F2 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| February 09, 2018 Filed Feb 12, 2018 21:29 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | GrantStock Options (right to buy) · Derivative | 86,762 | $0.00 Strike: $18.61 | $0.00 |
DisclosureSEC source: 0001209191-18-009214 · doc4.xml · derivative · entry 1 Codner Iris Beck · CIK 0001721514 · EVP Global Brand&Communication 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 86,762 Underlying: Ordinary Shares · 86,762 shares Expires 2028-02-08 F1 · derivative.exercise_date: Stock options were granted on February 9, 2018, with 28,920 vesting on each of February 9, 2020 and February 9, 2021 and 28,922 vesting on February 9, 2022. F2 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.